DaVita Inc. (DVA): Price and Financial Metrics


DaVita Inc. (DVA)

Today's Latest Price: $117.48 USD

1.78 (-1.49%)

Updated Jan 27 3:42pm

Add DVA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

DVA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DVA is 7.33 -- better than 95.51% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 9.12 for Davita Inc; that's greater than it is for 89.72% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DVA comes in at 12.7% -- higher than that of 85.89% of stocks in our set.
  • Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are LAMR, CE, IRM, NUE, and NRG.
  • Visit DVA's SEC page to see the company's official filings. To visit the company's web site, go to www.davita.com.

DVA Stock Price Chart Interactive Chart >

Price chart for DVA

DVA Price/Volume Stats

Current price $117.48 52-week high $125.28
Prev. close $119.26 52-week low $62.20
Day low $116.90 Volume 405,836
Day high $118.96 Avg. volume 585,642
50-day MA $114.47 Dividend yield N/A
200-day MA $91.84 Market Cap 13.16B

DaVita Inc. (DVA) Company Bio


DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.

DVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$117.48$204.32 71%

We started the process of determining a valid price forecast for Davita Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Davita Inc ranked in the 64th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 72.17%. In terms of the factors that were most noteworthy in this DCF analysis for DVA, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 57. Its equity weight surpasses that of merely 13.34% of free cash flow generating stocks in the Healthcare sector.
  • Davita Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 2.56% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%68%
1%70%
2%71%
3%73%
4%75%
5%76%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try ANTM, DGX, NVO, MCK, and FMS.


DVA Latest News Stream


Event/Time News Detail
Loading, please wait...

DVA Latest Social Stream


Loading social stream, please wait...

View Full DVA Social Stream

Latest DVA News From Around the Web

Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.

Hemodialysis And Peritoneal Dialysis Market Future Of Investment Market Share & Trends To 2028 DaVita Healthcare Partners Inc., Baxter International Inc., B. Braun Melsungen AG

Market Dynamics: With a substantial CAGR over the forecast period, the global demand for hemodialysis and peritoneal dialysis is likely to expand. Based on major segmentations, the main objective of this report is to analyze, identify, identify and assess the global

OpenPR | January 20, 2021

Renalytix and Davita join forces to identify and manage early-stage kidney disease

Diagnostics innovator Renalytix AI plc and dialysis giant Davita Inc. partnered to develop a program to identify individuals with early-stage kidney disease and improve outcomes for the 37 million Americans with chronic kidney disease (CKD). The companies plan to launch the collaborative effort in three cities in 2021 to build a diverse, real-world evidence dataset as a base for moving forward.

BioWorld | January 13, 2021

Global Medical - Social Working Services Market Challenges, Growth, Countries, Revenue & Forecast 2027||Top Companies-Kaiser Permanente; DaVita Inc; Universal Health Services, Inc.; Quest Diagnostics Incorporated

Data bridge Market research provides a report in which the Medical - Social Working Services market drivers and regulations are derived from a famous SWOT analysis technique. We’ve taken up their organization profiles to really understand those key gamers

OpenPR | January 8, 2021

Fresenius Medical Care Is A Global Market Leader And A Bargain

Introduction My wealth management is essentially based on two principles or goals. The first goal should always be to preserve current wealth. Only the second step should be to increase wealth. So look first at the risk, then at the opportunities. I have been looking at Fresenius Medical Care (FMS)...

The European View on Seeking Alpha | January 5, 2021

Why BofA Is Upgrading Tenet Healthcare, Downgrading DaVita

DaVita Inc. (NYSE: DVA ) is focused on dialysis, which means that it is unlikely to get much of a boost from a reacceleration in volumes within health care, of which Tenet Healthcare Corp (NYSE: THC ) is a key beneficiary, according to BofA Securities. The Health Care Analyst: Kevin Fischbeck downgraded DaVita from Buy to Neutral and raised the price target from $122 to $127. In a separate note, the analyst upgraded Tenet Healthcare from Neutral to Buy and raised the price target from $45 to $50. The Health Care Thesis: The Medicare rate environment is positive, and DaVita should continue to exhibit strong cost … Full story available on Benzinga.com

Benzinga | January 5, 2021

Read More 'DVA' Stories Here

DVA Price Returns

1-mo 1.76%
3-mo 36.97%
6-mo 34.43%
1-year 41.71%
3-year 48.52%
5-year 75.03%
YTD 0.07%
2020 56.47%
2019 45.80%
2018 -28.78%
2017 12.54%
2016 -7.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0165 seconds.